---
title: "MDGL.US (MDGL.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MDGL.US/news.md"
symbol: "MDGL.US"
name: "MDGL.US"
parent: "https://longbridge.com/en/quote/MDGL.US.md"
datetime: "2026-05-20T10:07:47.695Z"
locales:
  - [en](https://longbridge.com/en/quote/MDGL.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MDGL.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MDGL.US/news.md)
---

# MDGL.US (MDGL.US) — Related News

### [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
*2026-05-17T14:05:26.000Z*
> Madrigal Pharmaceuticals reported a Q1 2026 net loss of $94.39 million, up from $73.24 million a year prior, despite str

### [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://longbridge.com/en/news/285995344.md)
*2026-05-11T20:31:12.000Z*
> On May 1, 2026, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) based in Conshohocken, Pennsylvania, disclosed that it prov

### [Domestic FIC has made it to the MNC must-buy list?](https://longbridge.com/en/news/285946678.md)
*2026-05-11T12:05:06.000Z*
> Madrigal's THR-β agonist Rezdiffra is the world's first approved treatment for MASH, expected to be launched in Q2 2024,

### [Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays](https://longbridge.com/en/news/285701382.md)
*2026-05-08T09:55:27.000Z*
> Barclays analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a price target of $964

### [Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)](https://longbridge.com/en/news/285571177.md)
*2026-05-07T14:01:50.000Z*
> Bank of America Securities analyst Jason Zemansky has maintained a Hold rating on Madrigal Pharmaceuticals (MDGL) with a

### [<![CDATA[Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial]]>](https://longbridge.com/en/news/285421024.md)
*2026-05-06T18:15:43.000Z*
> Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, with $300 million upfront. Madrigal Pharmaceut

### [Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call](https://longbridge.com/en/news/285387459.md)
*2026-05-06T13:23:26.000Z*
> Madrigal Pharmaceuticals reported impressive Q1 2026 results, with net sales of $311 million, a 127% increase year-over-